Evidence map›Paper›PMID 37514191›Full record

ReviewPharmaceutics2023

Next-Generation Nanomedicine Approaches for the Management of Retinal Diseases.

Binapani Mahaling, Shermaine W Y Low, Sanjay Ch, Utkarsh R Addi, Baseer Ahmad, Thomas B Connor, Rajiv R Mohan, Swati Biswas, Shyam S Chaurasia

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. The In Vitro Enhancement of Retinal Cell Viability via mInternational journal of molecular sciences · 2024
    Article
  9. Nanomedicine in Ophthalmology: From Bench to Bedside.Journal of clinical medicine · 2024
    Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Binapani MahalingOcular Immunology and Angiogenesis Lab, Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Shermaine W Y LowOcular Immunology and Angiogenesis Lab, Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Sanjay ChNanomedicine Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad 500078, India.
Utkarsh R AddiOcular Immunology and Angiogenesis Lab, Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Baseer AhmadOcular Immunology and Angiogenesis Lab, Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0002-2216-4263
Thomas B ConnorOcular Immunology and Angiogenesis Lab, Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Rajiv R MohanOne-Health One-Medicine Ophthalmology and Vision Research Program, University of Missouri, Columbia, MO 65211, USA.ORCID 0000-0002-1857-4200
Swati BiswasNanomedicine Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad 500078, India.ORCID 0000-0002-1575-4206
Shyam S ChaurasiaOcular Immunology and Angiogenesis Lab, Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0001-8725-676X
Medical College of Wisconsin · USBirla Institute of Technology and Science, Pilani · INUniversity of Missouri Health System · US

Funding

Diagnosis and Predictive Value of the Ocular Manifestations of Fabry DiseaseR01EY030077 · NEI · MEDICAL COLLEGE OF WISCONSIN · PI CHAURASIA, SHYAM SUNDER · 2019 to 2023
$2.6M
Role of S100 proteins in Diabetic RetinopathyR01EY029795 · NEI · UNIVERSITY OF MISSOURI-COLUMBIA · PI CHAURASIA, SHYAM SUNDER · 2019 to 2023
$2.2M
National Institute of Health R01EY029795 and R01EY030077NEI NIH HHS R01 EY029795NEI NIH HHS R01 EY030077
6 · The paper itself

Abstract

Retinal diseases are one of the leading causes of blindness globally. The mainstay treatments for these blinding diseases are laser photocoagulation, vitrectomy, and repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF) or steroids. Unfortunately, these therapies are associated with ocular complications like inflammation, elevated intraocular pressure, retinal detachment, endophthalmitis, and vitreous hemorrhage. Recent advances in nanomedicine seek to curtail these limitations, overcoming ocular barriers by developing non-invasive or minimally invasive delivery modalities. These modalities include delivering therapeutics to specific cellular targets in the retina, providing sustained delivery of drugs to avoid repeated intravitreal injections, and acting as a scaffold for neural tissue regeneration. These next-generation nanomedicine approaches could potentially revolutionize the treatment landscape of retinal diseases. This review describes the availability and limitations of current treatment strategies and highlights insights into the advancement of future approaches using next-generation nanomedicines to manage retinal diseases.

Indexed as

nanodeliverynanodevicesnanomedicinesnanoparticlesnanostructured scaffoldsretina

Identifiers

PMID37514191
PMCPMC10383092
OpenAlexW4385172482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.